The purpose of this research is to assess the continued safety and efficacy of the Esprit BTK system, which was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of narrowed arteries below the knee in patients with Chronic Limb-Threatening Ischemia (CLTI).
Participants may enroll in the study if this stent is used during their procedure.
Study participation will last for three years, with follow-up visits (after the procedure) at 30 days, 90 days, 180 days, 1 year, 2 years, and 3 years.